High-sensitivity troponin I (hsTnI) and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) are predictors of coronary artery disease. Recently, routine hematological parameters emerged as mortality predictors. We examined the predictive value of hematological parameters (from the Utrecht Patient Oriented Database) and hsTnI and NT-pro-BNP for mortality in a coronary angiography population (Utrecht Coronary Biobank n ¼ 1913). Using Cox regression, receiver operating characteristics, integrated discrimination improvement (IDI), and continuous net reclassification improvement (cNRI) analysis, we compared the predictive properties of hematological parameters with hsTnI and NT-pro-BNP for mortality. During a median follow-up duration of 1.8 years, 77 deaths occurred. A panel of 7 hematological parameters (leukocyte count, reticulocyte mean corpuscular hemoglobin concentration, red blood cell [RBC] green (FL1) fluorescence, %neutrophils, %large [>120 fL] RBCs, %monocytes, and coefficient of variation of neutrophil complexity) was highly predictive. Added to clinical characteristics, hematological parameters (area under the curve [AUC]: 0.855, P < .001; IDI: 0.04, P ¼ .02; cNRI: 0.41, P < .001) were better predictors than hsTnI (AUC: 0.818) or NT-pro-BNP (AUC: 0.834) alone or combined (AUC: 0.834). Hematological parameters may provide mortality risk information following coronary angiography and may be superior to hsTnI and/or NT-pro-BNP.
Introduction
High-sensitivity troponin I 1 (hsTnI) and NT pro-brain natriuretic peptide 2 (NT-pro-BNP) constitute the current clinical gold standard biomarkers for diagnosis and prognosis in patients with acute myocardial infarction, 3 stable heart failure, 4 elective coronary angiography, 5 stable and unstable coronary artery disease (CAD), 6, 7 and percutaneous coronary intervention 8 (PCI). Recently, a different and easily accessible type of biomarker has emerged. Blood cell characteristics (counts and percentages), for example, from leukocytes 9, 10 and red blood cells (RBCs), 11 harbor prognostic information in diverse patient populations. Such hematological parameters are widely available and measured on a routine basis. Modern automated hematology analyzers automatically perform a whole blood cell count irrespective of the clinical request. While not routinely reported to the physician, the unrequested parameters can be extracted and stored for future reference. In the University Medical Center in Utrecht, blood cell differentiation data from the Abbott Sapphire (Santa Clara, California) 12 hematology analyzer have been stored in the Utrecht Patient Oriented Database (UPOD) 13 for research purposes. The measured parameters consist of cell counts, cell sizes, and other cell properties such as cell complexity and granularity.
As precise estimation mortality risk in patients with CAD is key for a patient-specific treatment policy and for accurate patient information, we compared the predictive power of routine hematological parameters with the current clinical standard, hsTnI and NT-pro-BNP, for prediction of mortality during 2 years of follow-up in patients with CAD undergoing coronary angiography.
Methods

Study Population
In this study, we analyzed data from the Utrecht Coronary Biobank (UCORBIO) cohort (registered as an observational study at clinicaltrials.gov, identifier: NCT02304744), an observational cohort study of patients with coronary angiography in the University Medical Center in Utrecht, the Netherlands. From October 2011 to December 2014, a total of 2591 patients were enrolled. For the current study, we selected adult (>18 years) patients presenting with myocardial infarction (either ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction), chest pain without release of cardiac enzymes (stable or unstable angina), dyspnea on exertion, silent ischemia, or screening for noncardiac surgery with complete case information (n ¼ 1913). Patients with other indications for coronary angiography (coronary anomalies, screening for cardiac surgery, or follow-up after heart transplantation) were excluded.
Ethics, Consent, and Permissions
All patients provided written informed consent and the study conforms to the Declaration of Helsinki. The institutional review board of the University Medical Centre Utrecht approved this study (registration number 11-183).
Data Collection
Data collection in the UCORBIO cohort has been described before.
14 In summary, standardized electronic case report forms were completed at baseline containing age, sex, cardiovascular risk factors, indication for angiography, medication use, angiographic findings, and eventual treatment of CAD. The angiographic findings were categorized into 4 groups by the treating interventional cardiologist: no CAD, minor CAD (wall irregularities, <50% stenosis), single-vessel disease (1 vessel with >50% stenosis 15 ), and multivessel disease (2 or 3 vessels with >50% stenosis).
Plasma Biomarkers
Plasma biomarkers (hsTnI and NT-pro-BNP) were measured in thawed EDTA plasma, which had been drawn directly prior to coronary angiography from the arterial sheath, before heparinization and immediately stored at À80 C. High-sensitivity troponin I was measured using the STAT high-sensitive troponin-I assay on the ARCHITECT i2000 analyzer (Abbott Park, Chicago, Illinois). N-terminal pro-brain natriuretic peptide was measured using a semi-automated ELISA robot (Freedom EVO; Tecan, Mannedorf, Switzerland, antibodies: 15C4 and biotinylated 13G12; HYTest, Turku, Finland).
Hematological Parameters
Hematological parameters were obtained through complete blood count analysis at inclusion from the same blood sample as the plasma biomarkers. Fifty-six routinely measured RBC, leukocyte, and platelet parameters from the UPOD database were initially taken into consideration in this study. 13 All hematological parameters were measured using the Cell-Dyn Sapphire 16 hematology analyzer (Abbott Diagnostics, Santa Clara, California). This analyzer is equipped with an integrated 488-nm blue diode laser and uses spectrophotometry, electrical impedance, laser light scattering (multiangle polarized scatter separation), and 3-color fluorescent technology to measure morphological parameters of leukocytes, RBCs, and platelets for classification and enumeration. The morphological parameters entail the following 5 optical scatter signals for leukocytes: cell size (0 scatter, axial light loss), cell complexity and granularity ( 
Statistical Analysis
Baseline characteristics are reported as means and SDs for continuous variables and percentages for categorical variables, both for the entire cohort and for survivors and nonsurvivors separately.
First, we constructed a clinical risk prediction model. Covariates for this model were selected using a backward stepwise Cox regression model for all-cause mortality, which comprised age, sex, diabetes, hypercholesterolemia, smoking status, indication for angiography, angiographic CAD severity, history of PCI, history of acute coronary syndrome, kidney failure, and treatment following angiography. The model with the lowest Akaike information criterion was selected. Assumptions for Cox regression were checked and satisfied.
To determine a predictive panel of hematological parameters, we first evaluated mutual correlation of the parameters (total n ¼ 56) by means of hierarchically clustered heat map analysis, grouping closely related parameters in a cluster. From each cluster of collinear parameters (Spearman R > .6 or < À.6), the parameter with the strongest relation with all-cause mortality was selected for further analysis. The remaining parameters (n ¼ 34, Supplemental Table 1 ) were entered in a backward stepwise Cox regression model. Subsequently, the top 10 significant parameters were added to the clinical model (which was coerced to stay in the model), and backward stepwise Cox regression was performed again to determine the final panel of hematological parameters. Abbreviations: ACE, angiotensin-converting enzyme, ACS indicate acute coronary syndrome, BMI, body mass index; CAD, coronary artery disease; CABG, coronary artery bypass grafting, CVA, cerebrovascular accident; EF, ejection fraction; FU, follow-up; hsTnI, high-sensitivity troponin I; IQR, interquartile range; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; PAD, peripheral arterial disease; UAP, unstable angina pectoris; UCORBIO, Utrecht Coronary Biobank.
Receiver operating characteristic analysis was performed to assess the prognostic value of hsTnI, NT-pro-BNP, and the panel of hematological parameters in addition to the clinical model. The clinical model was entered as a linear predictor to stabilize its predictive value. Next, we evaluated the prognostic value of adding hsTnI, NT-pro-BNP, or both to the panel of hematological parameters (all on top of the clinical model).
For visualization of the predictive value of the panel of hematological parameters, a linear predictor was constructed, and the predicted risk based on this linear predictor was divided into quartiles. Survival, adjusted for the clinical parameters, was subsequently plotted for these quartiles.
Internal validation of the predictive properties of the hematological parameters was performed by means of postestimation parameter-wise shrinkage 17 using the jackknife method (repeating the analysis leaving out 1 observation at a time). For this purpose, we used the "shrink" package 18 for R. Also, optimism-adjusted areas under the curve (AUCs) were calculated using a bootstrapping method.
Furthermore, continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI) measures for the abovementioned comparisons were calculated using the "survIDINRI" package 19 to assess risk prediction improvement. The cNRI corresponds to the percentage of patients that is correctly reclassified by the addition of a new parameter to the previous Cox model and is calculated by adding the percentage of deceased patients who appropriately had higher predicted risk in the new model to the percentage of alive patients who appropriately had a lower predicted risk in the new model. 20 Continuous NRI was deemed preferable over categorical NRI due to the lack of established meaningful risk categories in secondary risk prediction. 21 The IDI corresponds to the absolute change in predicted risk between the old and the new model. It is calculated by subtracting the difference in predicted risk between deceased and alive patients in the old model from the difference in predicted risk between deceased and alive patients in the new model. 22 Additionally, we created optimism-adjusted calibration plots using bootstrapping (repeating the analysis using random resampling with replacement, n ¼ 40) to assess the model fit.
All statistical analyses were performed using Rstudio and the R software package (version 3.1.2, Vienna, Austria).
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A 2-sided P < .05 was considered significant.
Results
Patient Characteristics
During a median follow-up duration of 1.8 years, 77 deaths occurred; 29 of which from cardiovascular events. Patient characteristics are shown in Table 1 , stratified by mortality status during follow-up. Patients who died during the follow-up period were older (73 vs 63 years, P < .001) and more frequently diabetic than survivors (38% vs 22%; P ¼ .002). Patients who died during follow-up more often had a history of coronary artery bypass grafting surgery, peripheral arterial disease, kidney failure, and impaired left ventricular function. Angiotensinconverting enzyme inhibitor (48% vs 34%; P ¼ .018) and diuretic use were significantly more common in deceased patients (55.8% vs 27.4%; P < .001). Median hsTnI levels (22.3 vs 7.1 ng/mL; P < .001) and NT-pro-BNP levels (260.5 vs 83.0 pmol/ L; P < .001) were significantly higher in deceased patients. The multivariable adjusted hazard ratio (HR) of hsTnI and NT-pro-BNP for mortality during follow-up was 1.00 [0.93-1.08] per 1000 ng/mL increase, P ¼ .945, and 1.27 [1.14-1.42] per 1000 pmol/L increase, P < .001, respectively.
Hematological Parameters
Backward Cox regression was performed as described above, providing a panel of 7 hematological parameters. The levels of the hematological parameters for deceased and alive patients and multivariable adjusted HRs are displayed in Table 2 
All-Cause Mortality Prediction
We first evaluated the additive predictive value of hsTnI, NT-pro-BNP, and hematological parameters to a clinical model (Table 3, Abbreviations: cNRI, continuous net reclassification improvement; hsTnI, high-sensitivity troponin I; IDI, integrated discrimination improvement; NT-pro-BNP, Nterminal pro-brain natriuretic peptide. We then assessed whether hsTnI, NT-pro-BNP, or their combination could improve prediction in addition to the clinical model enriched by the hematological parameters (Table 3 bottom; Figure 1B) . Addition of NT-pro-BNP (AUC: 0.863 vs 0.855; P ¼ .044) alone or in combination with hsTnI slightly but significantly improved prediction (AUC: 0.865, P ¼ .028). Neither hsTnI, NT-pro-BNP, nor their combination could significantly improve reclassification on top of the hematological parameters ( cNRIs all nonsignificant, Table 3 ), while discrimination was slightly improved (Table 3) .
Bootstrapped calibration plots were created (Supplemental Figure 1 ) in order to assess goodness of fit. Addition of hematological parameters to the clinical model significantly increased the R 2 (from 0.119 to 0.177, P < .001), reflecting a better fit. When hsTnI was added to the model, it did not further improve the model fit. However, the addition of NT-pro-BNP slightly increased model fit (R 2 increased to 0.190, P ¼ .003). Optimism-adjusted AUCs provided similar results compared with the AUCs derived from our original models (Supplemental Figure 3 ).
Internal Validation
Models based on a single data set tend to result in overfitting and overoptimistic estimates. Therefore, our model was internally validated by means of postestimation shrinkage. The predicted all-cause mortality risk based on the initial model including hematological parameters was grouped into quartiles (Q1-Q4). Adjusted survival curves are shown in Figure 2 . Hazard ratio for Q3 versus Q1 and Q4 versus Q1 were 6.6 (2.0-21.9), P ¼ .002 and 9.6 (3.0-31.2)], P < .001, respectively. After shrinkage, the HR for Q2 versus Q1 remained nonsignificant. Hazard ratio for Q3 versus Q1 and Q4 versus Q1 were 3.2 (2.0-5.2), P ¼ .010 and 4.8 (3.2-7.0), P < .001, respectively.
Discussion
Our study shows superiority of hematological parameters over the current clinical standard, hsTnI and NT-pro-BNP, for mortality prediction in patients with CAD undergoing coronary angiography. The resulting panel of parameters comprises leukocyte and RBC characteristics. Both leukocyte and RBC characteristics have previously been reported to serve as strong predictors of mortality in various patient groups.
In patients with cardiovascular disease, leukocyte characteristics have been tested and compared with the established marker high-sensitivity C-reactive protein (hsCRP). In stable patients with CAD undergoing coronary angiography, neutrophil count was superior to hsCRP in predicting cardiovascular mortality. 9 In our study, we also included RBC and platelet characteristics as potential predictors of mortality. High platelet reactivity is an independent predictor of future adverse events in patients with myocardial infarction and thus seemed to be a logical candidate for testing. 24 Unexpectedly, none of the platelet characteristics (plateletcrit, mean platelet volume, platelet distribution width, CV of platelet granularity, and reticulated platelet count) in UPOD added any predictive value to the clinical model in our study; mean platelet volume did, however, predict mortality in univariable analysis in agreement with the literature. 25 The reasons can be manifold. Our study population mainly consists of stable patients with CAD, which have a lower risk of acute fatal thrombotic events due to high platelet reactivity than patients with myocardial infarction. Hence, the role of platelets in this cohort might be less relevant. More likely though, the predictive value of platelet characteristics is also reflected by other hematological parameters in our multivariable model, rendering it nonsignificant. Another possibility is that high platelet reactivity is not reflected by their morphology as measured by the hematology analyzers, supporting the need for separate platelet activation testing in high-risk patients. Finally, though our analyses did not investigate such effects, the lack of platelet markers might be due to platelet inhibitors given to the vast majority of patients included in this study.
In contrast, both leukocyte and RBC parameters provided additional predictive value. Monocytes have long been known for their causal role in plaque initiation, progression, and destabilization. 26 As previously shown, their numbers correlate with the presence of cardiovascular disease and higher interleukin 6 levels and predict all-cause and cardiovascular mortality. 27, 28 Recent studies have shown the direct involvement of neutrophils in cardiovascular disease. Neutrophil depletion significantly reduced plaque formation in mice. 29 Furthermore, neutrophils can be found in high numbers in coronary artery autopsy specimens from patients who died of myocardial infarction. 30 In addition to neutrophil numbers, we found additional predictive value of the variation in neutrophil complexity. This can be regarded as an indication of a "left shift" or neutrophil activation as frequently seen in acute infections. 31 Morphological changes of neutrophils have also recently been described to correlate with cardiac function after acute myocardial infarction in a porcine model. 32 The observed "left shift" could thus reflect subclinical chronic inflammation due to prevailing coronary atherosclerosis or subacute myocardial ischemia. This is supported by the interaction between neutrophil numbers and morphology on one side and atherosclerosis and ischemia (or vice versa 29 ) on the other. The exact mechanisms relating these neutrophil characteristics to increased mortality risk however remain to be elucidated.
The role of RBCs in atherosclerosis is less clear. Nevertheless, they harbor significant predictive value in various diseases. In particular, RBC distribution width [33] [34] [35] (RDW), which reflects the variation in RBC volume, has been proposed as a powerful risk indicator of mortality.
11 Red blood cell volume is inversely related to RBC age; young cells are largest, and senescent cells are smaller. 36 Red blood cell characteristics, particularly the percentage of large (ie, young) RBCs that independently predicted mortality in our study, concurred with a higher proportion of young erythrocytes (closely related to RDW, r ¼ .21; P < .001). Red blood cell green (FL1) fluorescence, which was associated with worse survival in our study, reflects the amount of residual RNA in young erythrocytes and reticulocytes. Thus, it could reflect a higher percentage of young RBC, but its clinical relevance remains unclear.
Together with the MCHCr, markers of an immature RBC population with a low reticulocyte hemoglobin concentration are thus related to a higher risk of mortality in patients with coronary angiography.
To our surprise, we did not find any predictive value of hsTnI in our cohort. High-sensitivity troponin T (hsTnT) has been reported by several other groups as a potential predictor of mortality, for example, in stroke 37 after cardiac surgery 38 and after elective coronary angiography. 5 Possibly, this finding is due to differential prognostic properties of hsTnI and hsTnT, as reported by de Antonio et al. 39 High BNP levels are predictive of adverse events in a population of stable patients with CAD, 6 and NT-pro-BNP has been shown to predict mortality in an unstable CAD population. 40 Our study is in line with others, showing that the predictive value of NT-pro-BNP for mortality is superior to hsTnI. 41 Nevertheless, hematological parameters in our study outperformed both NT-pro-BNP and hsTnI for prediction of mortality (AUC: 0.855 vs 0.834). Apparently, blood cell characteristics provide more prognostic information than the cardiac-specific biomarkers hsTnI and/or NT-pro-BNP.
The hematological parameters included in our panel are of leukocyte (total leukocyte count, neutrophil %, monocyte %, and neutrophil complexity CV) and RBC origin (MCHCr, RBC green [FL1] fluorescence, and %large RBCs). Leukocyte 42 and neutrophil counts 43 have previously been described as prognostic markers for mortality in a population-based cohort. Neutrophil count was not included in our analysis due to its collinearity (r ¼ .68; P < .001) with neutrophil %, which was included as it had a stronger association with mortality.
The reason that blood cells may convey more accurate prognostic information than cardiac-specific biomarkers could be related to the organ-specificity of hsTnI and NT-pro-BNP. The end point in our study was all-cause mortality, meaning that not all deaths were due to cardiovascular disease or its consequences per se. Hematological parameters could provide a general whole-body overview of an individual's health status and subsequent prognosis. Therefore, we performed an additional analysis for cardiovascular death only. Again, hematological parameters outperformed hsTnI and NT-pro-BNP (AUC: 0.882 vs. 0.868, Supplemental Figure 2) . However, the number of cardiovascular deaths was low (n ¼ 29), and these data should thus be interpreted with caution.
In this article, the clinical parameters were analyzed as a linear predictor, meaning that the predictive value of these parameters was kept fixed when adding new hematological parameters. This might be a limitation to this study.
Several groups have investigated the relation between statin use and hematological parameters. 44, 45 In our study, our results did not change when adding statin use to the prediction model, also there was no interaction between statin use and the predictive value of hematological parameters (P interaction ¼ .9).
In the past few years, many hematological parameters and ratios have been proposed for prediction in cardiovascular diseases, such as the leukocyte count, 46 monocyte to lymphocyte ratio, 10 neutrophil to lymphocyte ratio, 47 and so on. Although it is unclear which hematological parameter will prove to be the best predictor, it logically makes sense that a panel of several hematological parameters is more accurate than a single parameter or ratio between two, as proposed in this article. External validation of our findings remains indicated.
Conclusions
Hematological parameters outperform the established biomarkers hsTnI or NT-pro-BNP alone or in combination in predicting all-cause mortality after coronary angiography. Hence, readily available hematological parameters may provide a useful tool to improve current risk prediction algorithms (possibly integrated within the hematology analyzer linked to the electronic patient records) for all-cause mortality in coronary angiography patients. Although we put every effort in validating our model internally, external validation is warranted to investigate the clinical use of these
